Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
出版年份 2020 全文链接
标题
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
作者
关键词
-
出版物
CELL RESEARCH
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-27
DOI
10.1038/s41422-020-0375-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
- (2020) Sunil Pancholi et al. ONCOGENE
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
- (2019) Jordi Rodon et al. NATURE MEDICINE
- SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
- (2019) Charu Aggarwal et al. Journal of Thoracic Oncology
- Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
- (2019) Corey J. Langer et al. Journal of Thoracic Oncology
- Brief Report: SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study)
- (2019) Martin J. Edelman et al. Journal of Thoracic Oncology
- Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity
- (2019) Andres Canela et al. MOLECULAR CELL
- Chromatin regulators mediate anthracycline sensitivity in breast cancer
- (2019) Jose A. Seoane et al. NATURE MEDICINE
- Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro
- (2018) Valentina Citi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
- (2018) Alexander Ring et al. Cancers
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Breast cancer
- (2017) Nadia Harbeck et al. LANCET
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Tyrosyl–DNA phosphodiesterases: rescuing the genome from the risks of relaxation
- (2017) Ajinkya S Kawale et al. NUCLEIC ACIDS RESEARCH
- Protein tyrosine phosphatase receptor-type δ acts as a negative regulator suppressing breast cancer
- (2017) Xiaotang Yu et al. Oncotarget
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- (2016) Vassiliki Papadimitrakopoulou et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
- (2016) Celine Lefebvre et al. PLOS MEDICINE
- Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
- (2015) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Clinicopathological significance of ARID1B in breast invasive ductal carcinoma
- (2015) Fei Shao et al. HISTOPATHOLOGY
- The Platform Trial
- (2015) Scott M. Berry et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased metastasis with loss of E2F2 in Myc-driven tumors
- (2015) Inez Yuwanita et al. Oncotarget
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now